Clinical Trials
21 trialsNCT02478099 2024-05-03
MPDL3280A-treatment-IST-UMCG
University Medical Center Groningen
Phase 2 Unknown
NCT04739670 2024-03-01
BELLA
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05266937 2024-02-01
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Consorzio Oncotech
Phase 2 Unknown
NCT05833126 2023-12-15
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04659382 2023-08-18
SIRTCI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT03363867 2023-08-07
BEACON
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05038657 2022-10-03
AURORA
University Hospital Southampton NHS Foundation Trust
Phase 2 Unknown
NCT05396937 2022-05-31
Efficacy and Safety of T+A+RAD in HCC
Fudan University
Phase 2 Unknown
NCT03262454 2022-04-06
Atezolizumab
National Cancer Center, Korea
Phase 2 Unknown
NCT05034055 2021-09-05
SKYROCKET
Yonsei University
Phase 2 Unknown
NCT04739202 2021-03-29
IMMUNOGAST
Hospices Civils de Lyon
Phase 2 Unknown
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03647956 2019-04-17
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
The University of Hong Kong
Phase 2 Unknown
NCT03620435 2018-08-13
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Unknown
NCT03616691 2018-08-06
Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC
Samsung Medical Center
Phase 2 Unknown